Infectious Bursal Disease Vaccine Market
Report ID: SQMIG35H2413
Report ID: SQMIG35H2413
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2413 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
88
|Figures:
76
Global Infectious Bursal Disease Vaccine Market size was valued at USD 290.0 Million in 2024 and is poised to grow from USD 313.49 Million in 2025 to USD 584.56 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The primary driver of the infectious bursal disease vaccine market is the intensification and globalization of poultry production, which has increased flock density and international trade and therefore raised disease transmission risks and economic vulnerability. This market supplies vaccines to prevent infectious bursal disease, a highly contagious viral illness that undermines immune competence in young chickens and causes major productivity losses, so demand is sustained by producers seeking biosecurity and flock health. Over the past three decades vaccine portfolios evolved from basic live-attenuated strains toward immune-complex, recombinant and vector-based platforms, for example, the shift in Southeast Asia following recurrent outbreaks.A key factor accelerating the Global Infectious Bursal Disease Vaccine Market is technological innovation that translates pathogen surveillance into more effective immunization strategies, because improved molecular diagnostics detect variant strains early and thereby compel vaccine manufacturers to develop recombinant and vectored products tailored to local genotypes. Consequently producers adopt immune-complex or in-ovo delivery in commercial hatcheries to reduce early mortality and enhance uniform immunity, which yields demonstrable ROI through higher feed conversion and reduced antibiotic usage. Regulatory harmonization and strategic partnerships between poultry integrators and biotech firms further create market opportunities for contract manufacturing and region-specific vaccine portfolios and exports.
How is AI improving demand forecasting in the Infectious bursal disease vaccine market?
AI is improving demand forecasting in the Infectious bursal disease vaccine market by bringing together farm level signals supply chain data and external indicators to generate more accurate and timely demand insight. Key aspects include machine learning models that learn strain patterns and seasonality natural language processing that extracts outbreak reports and real time data integration from hatcheries and distributors. The current state shows a shift from static historical forecasts to adaptive systems that reduce waste align production with regional risk and help manufacturers and poultry producers coordinate vaccination schedules and inventory.Boehringer Ingelheim February 2025, the company launched a trivalent vaccine including infectious bursal disease protection which underlines market consolidation. AI driven forecasting helps firms anticipate demand for such innovations align hatchery output with regional needs and reduce stockouts which supports smoother market growth and operational efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 290.0 Million
Largest Segment
Live Attenuated Vaccine
Fastest Growth
Inactivated Vaccine
Growth Rate
8.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global infectious bursal disease vaccine market is segmented by vaccine type, administration route, end user and region. Based on vaccine type, the market is segmented into Live Attenuated Vaccine and Inactivated Vaccine. Based on administration route, the market is segmented into Injectable and Oral. Based on end user, the market is segmented into Poultry Farms, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Live attenuated segment dominates because longstanding clinical effectiveness and broad immune stimulation make it the preferred choice for flock protection, driving manufacturer focus and veterinarian recommendations. Its ability to induce durable immunity with single dose schedules reduces operational complexity and cost of disease management, which in turn sustains uptake and investment in production capacity. The established safety profile and integration into routine vaccination programs reinforce market leadership through steady demand and supply chain prioritization.
However, inactivated vaccines are emerging as the most rapidly expanding area due to improved antigen formulation and adjuvant advances that enhance safety for young flocks. Their suitability for combination products and compatibility with maternal antibodies is spurring regulatory support and commercial collaboration, creating broader product pipelines and distribution opportunities that drive future market growth.
Injectable segment dominates because precise dosing reliability and established administration protocols ensure consistent immune responses across diverse poultry breeds, leading veterinarians to favor injectable delivery for targeted immunization campaigns. The controlled delivery reduces variability in vaccine uptake, which supports predictable flock health outcomes and fosters manufacturer emphasis on injectable formulations. Training infrastructure and supply chains built around injections further entrench this route as the default in many commercial vaccination programs.
Meanwhile, oral administration is witnessing strong growth as mass delivery approaches reduce labor and allow whole flock immunization without individual handling. Advances in formulation stability and delivery vehicles that maintain efficacy in water or feed expand practical use, prompting producers to adopt scalable vaccination approaches that create new commercial opportunities and product innovations.
To get detailed segments analysis, Request a Free Sample Report
Asia Pacific dominates due to a convergence of structural and operational strengths that favor vaccine development, production, and uptake. High concentration of commercial poultry production and recurring disease pressure create strong demand for preventive measures, while regional manufacturers focus on cost-efficient large scale production. Supportive regulatory frameworks and public-private collaboration enable rapid approval and distribution of adapted vaccine formulations. Investment in veterinary research and diagnostic capacity allows targeted immunization strategies, and established cold chain logistics across major supply corridors sustain potency. Export oriented production and cross border collaboration among research institutions further strengthen market resilience, giving the region strategic advantage in innovation, manufacturing scalability, and market reach. Collaborations with global developers and investment in tailored vaccination programs accelerate adoption of novel formulations, while emphasis on biosecurity and surveillance strengthens demand for reliable immunization solutions. Diversified product portfolios targeting local viral variants and pricing strategies enhance accessibility across scales, consolidating leadership.
Infectious Bursal Disease Vaccine Market Japan emphasizes stringent quality standards and advanced vaccine platforms driven by coordinated public veterinary efforts. Strong research infrastructure and close collaboration between manufacturers and poultry integrators support development of tailored immunization approaches. Regulatory clarity and emphasis on biosecurity promote adoption of improved formulations, while attention to cold chain integrity and diagnostic support ensures deployment across operations and contributes to sustained demand for reliable vaccine solutions.
Infectious Bursal Disease Vaccine Market South Korea benefits from a dynamic biotechnology sector and manufacturing base that support rapid translation of research into scalable vaccine products. Close ties between manufacturers and poultry producers enable customized vaccination schedules and supply. Emphasis on innovation and quality control, combined with strong distribution networks and veterinary advisory services, fosters adoption of combination vaccine options tailored to local viral profiles and operational needs and sustainability.
Rapid expansion in North America is propelled by a combination of industry consolidation, technological adoption, and strong veterinary services that prioritize flock health. Integrated poultry operations and proactive disease management programs drive consistent vaccine uptake, while large animal health companies and local manufacturers push forward advanced vaccine types and improved delivery systems. A mature regulatory environment and robust diagnostic networks support swift identification of outbreaks and targeted immunization responses. Distribution efficiency, veterinarian advisory models, and collaborative research between academic institutions and industry further catalyze market growth. Emphasis on biosecurity, traceability, and quality assurance enhances trust in vaccine performance, encouraging broader adoption across commercial production systems and reinforcing the region role as a key market for innovative immunization solutions. Private sector investment in manufacturing capacity and supply chain resilience further supports consistent availability of vaccine options to meet diverse producer needs.
Infectious Bursal Disease Vaccine Market United States is characterized by integrated commercial poultry systems that prioritize coordinated vaccination strategies and veterinary oversight. Strong presence of animal health companies and manufacturers accelerates development and distribution of advanced formulations. Extensive diagnostic laboratories and services enable rapid response to disease threats, informing targeted immunization programs. Focus on biosecurity, traceability and quality control, with cold chain networks, supports reliable vaccine deployment across production segments.
Infectious Bursal Disease Vaccine Market Canada features a dispersed production landscape that favors adaptable immunization strategies and strong support from veterinary services. Collaboration between domestic manufacturers and research centers drives development of vaccines suited to regional viral challenges. Emphasis on biosecurity, traceability and producer outreach helps align on-farm practices with vaccination programs. Regulatory clarity and partnerships sustain availability of quality vaccine solutions across remote and urban production areas for producers.
Europe is strengthening its position through coordinated regulatory harmonization, concentrated scientific expertise, and investments in next generation vaccine technologies that respond to regional viral diversity. Strong collaboration among universities, contract manufacturers and established animal health companies fosters development of differentiated products and streamlined pathways to market. Emphasis on animal welfare and stringent quality standards drives demand for safe, effective formulations, while integrated veterinary networks and diagnostic capacity enable evidence based immunization programs. Cross border distribution channels and export orientation support manufacturer scale, and targeted public and private research initiatives accelerate translation of innovative platforms into practical solutions for producers across the continent. Standardization of vaccination protocols, development of regional strain banks and investment in cold chain and digital monitoring tools enhance practical deployment. Partnerships with global players and focused commercialization strategies further elevate competitiveness.
Infectious Bursal Disease Vaccine Market Germany leverages a strong biotechnology and manufacturing base to develop high quality vaccine formulations and delivery systems. Close cooperation among research institutes, manufacturers and animal health companies accelerates product refinement and regulatory readiness. Robust diagnostic networks and advisory services support evidence based immunization programs, while adherence to rigorous quality and safety standards positions manufacturers to serve local producers and international markets with targeted vaccine solutions.
Infectious Bursal Disease Vaccine Market United Kingdom benefits from leading academic research centers and collaboration with industry to advance novel vaccine platforms and delivery methods. Established veterinary advisory networks and trial capacity support evidence driven adoption and optimization of immunization protocols. Emphasis on animal welfare and rigorous regulatory compliance underpins trust in product safety, while export orientation and manufacturing capabilities enable producers to reach markets effectively with tailored vaccine solutions.
Infectious Bursal Disease Vaccine Market France combines strong research capabilities with a biotech sector to develop vaccines adapted to regional pathogen profiles. Collaboration between manufacturers, laboratories and producer associations supports tailored immunization strategies and validation. Regulatory alignment with continental frameworks and emphasis on product safety bolster market confidence. Well developed logistics and veterinary advisory networks facilitate distribution and adoption among commercial producers, further reinforcing national capacity for reliable vaccine supply.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand For Poultry Products
Advances In Vaccine Technology
Cold Chain Distribution Challenges
Regulatory Approval Complexity
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape for the global infectious bursal disease vaccine market is driven by incumbent product rollouts, consolidation and targeted biotech spin outs that shift capability to novel platforms. Companies are pursuing vectored trivalent launches and strategic partnerships while acquiring niche innovators to secure pipeline diversity, for example Boehringer Ingelheim’s VAXXITEK HVT plus IBD launch, Zoetis’ Poulvac Procerta introduction, the BiomEdit spin out and recent dealmaking by mid sized animal health groups.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the infectious bursal disease vaccine market is propelled by intensification and globalization of poultry production as a key driver, which raises disease risk and vaccination demand, while cold chain distribution challenges act as a notable restraint limiting reach into remote production areas. Asia Pacific is the dominating region given its large commercial flocks and manufacturing capacity, and live attenuated vaccines are the dominating segment due to established effectiveness and operational simplicity. A second driver is rapid technological innovation that turns pathogen surveillance and diagnostics into targeted recombinant and vector vaccine strategies. Together these dynamics favor consolidated players and tailored regional portfolios.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 290.0 Million |
| Market size value in 2033 | USD 584.56 Million |
| Growth Rate | 8.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Infectious Bursal Disease Vaccine Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Infectious Bursal Disease Vaccine Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Infectious Bursal Disease Vaccine Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Infectious Bursal Disease Vaccine Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
